OrbusNeich announced today that interim data from a prospective registry showed good safety in a broad population of patients that underwent primary percutaneous coronary intervention (PCI) and implantation of the company's Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI).
In the study of 652 consecutive STEMI patients, the rate of major adverse cardiac events (MACE) was 6.7 percent and the rate of subacute thrombosis was 1.1 percent at 30 days follow up. The interim data are presented in a poster by Jan-Henk Dambrink, M.D., Ph.D., of the Isala Klinieken, Zwolle, Netherlands, at the Transcatheter Therapeutics Conference in San Francisco.
"STEMI often presents challenges to interventional cardiologists as the condition can result in delayed stent endothelialization and lead to thrombosis with drug eluting stents," said Dambrink. "The interim data further support the safety profile of the Genous Bio-engineered R stent in this patient population as we confirm the low subacute stent thrombosis rate seen in several large trials for the Genous Bio-engineered R stent."
Harry Suryapranata, M.D., Ph.D., director of Diagram Clinical Research, Department of Cardiology, Isala Klinieken, added: "The interim results reflect a similar finding in a study of the Genous stent in 321 STEMI patients conducted at National University Hospital in Singapore. In the Singapore study, the early stent thrombosis rate was 0.9% with no further thrombotic events out to 12 months follow up."